PCI Biotech Holding ASA (PCIB.OL)
NOK 1.34
(0.38%)
NOK 1.34
(0.38%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -22.24 Million NOK | 60.6% |
| 2022 | -56.44 Million NOK | 34.39% |
| 2021 | -86.02 Million NOK | -4.76% |
| 2020 | -82.12 Million NOK | 7.53% |
| 2019 | -88.8 Million NOK | -99.47% |
| 2018 | -44.51 Million NOK | -2.51% |
| 2017 | -43.43 Million NOK | -31.5% |
| 2016 | -33.02 Million NOK | -1.22% |
| 2015 | -32.62 Million NOK | 10.54% |
| 2014 | -36.47 Million NOK | -24.37% |
| 2013 | -29.32 Million NOK | -7.21% |
| 2012 | -27.35 Million NOK | -60.19% |
| 2011 | -17.07 Million NOK | -5.13% |
| 2010 | -16.24 Million NOK | 8.16% |
| 2009 | -17.68 Million NOK | -45.71% |
| 2008 | -12.13 Million NOK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -4.12 Million NOK | 13.39% |
| 2024 Q2 | -4.12 Million NOK | 0.0% |
| 2023 Q2 | -6.32 Million NOK | 0.83% |
| 2023 FY | -25.23 Million NOK | 55.3% |
| 2023 Q4 | -4.76 Million NOK | 0.0% |
| 2023 Q3 | -4.76 Million NOK | 24.63% |
| 2023 Q1 | -6.37 Million NOK | 9.65% |
| 2022 Q4 | -7.06 Million NOK | 35.5% |
| 2022 FY | -56.44 Million NOK | 34.39% |
| 2022 Q1 | -22.8 Million NOK | 2.02% |
| 2022 Q2 | -15.64 Million NOK | 31.4% |
| 2022 Q3 | -10.94 Million NOK | 30.02% |
| 2021 Q4 | -23.27 Million NOK | -3.42% |
| 2021 Q2 | -19.08 Million NOK | 9.86% |
| 2021 Q1 | -21.17 Million NOK | 0.89% |
| 2021 FY | -86.02 Million NOK | -4.76% |
| 2021 Q3 | -22.5 Million NOK | -17.92% |
| 2020 Q2 | -22.25 Million NOK | -39.3% |
| 2020 Q3 | -22.53 Million NOK | -1.27% |
| 2020 Q4 | -21.36 Million NOK | 5.21% |
| 2020 FY | -82.12 Million NOK | 7.53% |
| 2020 Q1 | -15.97 Million NOK | 36.94% |
| 2019 FY | -88.8 Million NOK | -99.47% |
| 2019 Q2 | -27.05 Million NOK | -50.87% |
| 2019 Q4 | -25.33 Million NOK | -36.96% |
| 2019 Q3 | -18.49 Million NOK | 31.63% |
| 2019 Q1 | -17.92 Million NOK | -25.57% |
| 2018 FY | -44.51 Million NOK | -2.51% |
| 2018 Q4 | -14.27 Million NOK | -70.26% |
| 2018 Q3 | -8.38 Million NOK | -16.59% |
| 2018 Q2 | -7.19 Million NOK | 50.94% |
| 2018 Q1 | -14.66 Million NOK | 7.92% |
| 2017 Q4 | -15.92 Million NOK | -52.3% |
| 2017 FY | -43.43 Million NOK | -31.5% |
| 2017 Q1 | -9.85 Million NOK | -42.75% |
| 2017 Q2 | -7.2 Million NOK | 26.88% |
| 2017 Q3 | -10.45 Million NOK | -45.12% |
| 2016 Q1 | -7.3 Million NOK | 14.4% |
| 2016 FY | -33.02 Million NOK | -1.22% |
| 2016 Q4 | -6.9 Million NOK | 27.6% |
| 2016 Q3 | -9.53 Million NOK | -2.74% |
| 2016 Q2 | -9.28 Million NOK | -26.98% |
| 2015 Q3 | -9.41 Million NOK | -35.21% |
| 2015 FY | -32.62 Million NOK | 10.54% |
| 2015 Q1 | -7.71 Million NOK | 24.88% |
| 2015 Q2 | -6.96 Million NOK | 9.68% |
| 2015 Q4 | -8.53 Million NOK | 9.31% |
| 2014 Q1 | -9.4 Million NOK | -0.45% |
| 2014 Q2 | -8.38 Million NOK | 10.9% |
| 2014 Q3 | -8.41 Million NOK | -0.39% |
| 2014 Q4 | -10.26 Million NOK | -21.96% |
| 2014 FY | -36.47 Million NOK | -24.37% |
| 2013 Q1 | -7.24 Million NOK | 17.7% |
| 2013 Q2 | -5.89 Million NOK | 18.69% |
| 2013 Q3 | -6.9 Million NOK | -17.28% |
| 2013 Q4 | -9.36 Million NOK | -35.6% |
| 2013 FY | -29.32 Million NOK | -7.21% |
| 2012 Q1 | -6.2 Million NOK | -26.9% |
| 2012 Q4 | -8.8 Million NOK | -9.11% |
| 2012 Q3 | -8.06 Million NOK | -88.0% |
| 2012 Q2 | -4.29 Million NOK | 30.88% |
| 2012 FY | -27.35 Million NOK | -60.19% |
| 2011 Q1 | -4.03 Million NOK | 20.66% |
| 2011 FY | -17.07 Million NOK | -5.13% |
| 2011 Q2 | -5.12 Million NOK | -26.96% |
| 2011 Q3 | -3.01 Million NOK | 41.13% |
| 2011 Q4 | -4.89 Million NOK | -62.04% |
| 2010 Q3 | 1.03 Million NOK | 116.11% |
| 2010 Q1 | -5.71 Million NOK | -42.22% |
| 2010 FY | -16.24 Million NOK | 8.16% |
| 2010 Q2 | -6.39 Million NOK | -11.83% |
| 2010 Q4 | -5.09 Million NOK | -594.27% |
| 2009 Q4 | -4.01 Million NOK | 2.02% |
| 2009 Q3 | -4.1 Million NOK | 5.05% |
| 2009 Q2 | -4.32 Million NOK | 0.0% |
| 2009 FY | -17.68 Million NOK | -45.71% |
| 2008 FY | -12.13 Million NOK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Arctic Bioscience AS | -48.58 Million NOK | 54.224% |
| Aqua Bio Technology ASA | -17.85 Million NOK | -24.55% |
| ArcticZymes Technologies ASA | 15.74 Million NOK | 241.249% |
| BerGenBio ASA | -191.81 Million NOK | 88.405% |
| Hofseth BioCare ASA | -102.52 Million NOK | 78.308% |
| Thor Medical ASA | -7.16 Million NOK | -210.628% |
| Ultimovacs ASA | -215.73 Million NOK | 89.691% |